MAY 2 7 2011

510(k) Summary

ArthroCare Corporation Spartan™ PEEK Suture Implant System

General Information

Submitter Name/Address:

ArthroCare Corporation

680 Vaqueros Avenue

Sunnyvale, CA 94085-2936

Establishment Registration Number:

2951580

Contact Person:

Valerie Defiesta-Ng

Director, Regulatory Affairs

Date Prepared:

March 18, 2011

Device Description

Trade Name:

ArthroCare Spartan PEEK Suture Implant

System

Generic/Common Name:

Screw, Fixation, Bone

Classification Name:

Smooth or Threaded Metallic Bone Fixation

Fastener (21 CFR 888.3040)

Device Classification:

Class II, 21 CFR 888.3040

Product Code MBI

Predicate Device

ArthroCare 5.5mm Spartan PEEK Suture

K110164 (February 7, 2011)

Implant System

ArthroCare 5.5mm Spartan PEEK Suture

K102262 (October 21, 2010)

Implant System

Product Description

The ArthroCare Spartan PEEK (polyether-etherketone) Suture Implant is a fully-threaded, corkscrew shape anchor available in 5.5mm and 6.5mm diameter size. The suture anchor comes preconfigured with MagnumWire® sutures for traditional knot tying and is mounted on a disposable delivery driver. The device is supplied sterile and is available with our without needles. Associated instruments (Punch Tap and Extraction Tool) for implantation and removal of the implant are available separately and altogether are referred to as the ArthroCare Spartan PEEK Suture Implant System.

Intended Uses/Indications for Use

The ArthroCare Spartan PEEK Suture Implant is indicated for use in fixation of soft tissue to bone. Examples of such procedures include:

Shoulder: Bankart Repair, SLAP lesion repair, acromio-clavicular separation, rotator cuff repair, capsule shift/capsule-labral reconstruction, biceps tenodesis, and deltoid repair

Ankle: Lateral instability, medial instability, Achilles tendon repair/reconstruction, and midfoot reconstruction

Foot: Hallux valgus reconstruction

Elbow: Tennis elbow repair, biceps tendon reattachment

Knee: Extra-capsular repairs; reattachment of: medial collateral ligament, posterior oblique ligament or joint capsule closure to anterior proximal tibia; extra capsular reconstruction, ITB tenodesis; patellar ligament and tendon avulsions

Substantial Equivalence

In establishing substantial equivalence to the predicate, ArthroCare compared the intended use, device design, technology, and device components of the subject device with the predicate device. Bench performance testing has been completed to demonstrate the substantial equivalence of the ArthroCare Spartan PEEK Suture Implant in accordance with FDA Guidance Document Testing for Bone Anchors. The *in vitro* testing performed involved insertion of the anchors in a simulated human bone substrate followed by both ultimate strength and cyclic loading tests. The performance testing and device comparison demonstrate that the subject device is substantially equivalent to the predicate device, and is safe and effective for its intended use.

Summary of Safety and Effectiveness

The proposed modifications to the Spartan PEEK Suture Implant System are not substantial changes, and do not significantly affect the safety or efficacy of the proposed device.





Food and Drug Administration 10903 New Hampshire Avenue Document Control Room –WO66-G609 Silver Spring, MD 20993-0002

ArthoCare Corporation % Ms. Valerie Defiesta-Ng Director, Regulatory Affairs 680 Vaqueros Avenue Sunnyvale, California 94085-2936

MAY 2 7 2011

Re: K110781

Trade/Device Name: ArthoCare® Spartan™ PEEK Suture Implant System

Regulation Number: 21 CFR 888.3040

Regulation Name: Smooth or threaded metallic bone fixation fastener

Regulatory Class: Class II

Product Code: MBI Dated: May 13, 2011 Received: May 16, 2011

Dear Ms. Ng:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act

Page 2 – Ms. Valerie Defiesta-Ng

or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

G Mark N. Melkerson

Director

Division of Surgical, Orthopedic And Restorative Devices Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number (if known):		
Device Name:	ArthroCare® Sparta	in [™] PEEK Suture Implant System
Indications For Use:		
The ArthroCare Spartan tissue to bone. Examples	PEEK Suture Implant of such procedures inclu	is indicated for use in fixation of soft ide:
		cromio-clavicular separation, rotator ction, biceps tenodesis, and deltoid
Ankle: Lateral instability, midfoot reconstruction	, medial instability, Ach	illes tendon repair/reconstruction, and
Foot: Hallux valgus recor	struction	
Elbow: Tennis elbow repa	air, biceps tendon reattac	chment
Prescription Use XX (Part 21 CFR 801 Subpart D	AND/OR	Over-The-Counter Use (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE E	BELOW THIS LINE-CONT	INUE ON ANOTHER PAGE IF NEEDED)
Concurre	ence of CDRH, Office of D	evice Evaluation (ODE)
E: J/K (Division Sig	out	
Division of S and Restorati	urgical, Ormopeuts,	